Literature DB >> 19122742

Cancer Stem Cells in Hematopoietic Malignancies.

Richard J Jones1, Scott A Armstrong.   

Abstract

Most hematopoietic malignancies are comprised of cells that are functionally heterogeneous with only a subset being responsible for tumor maintenance. These cancer stem cells are so named because they possess qualities reminiscent of normal tissue stem cells including self-renewal, prolonged survival, and the ability to give rise to cells with more differentiated characteristics. Effort is now focused on identifying cancer stem cells in various hematopoietic malignancies, and defining the cells of origin such that the stepwise accumulation of genetic/epigenetic events necessary for cancer stem cell development can be delineated. A detailed understanding of these processes could lead to development of therapeutics that more effectively treat hematopoietic malignancies and potentially other cancers.

Entities:  

Year:  2008        PMID： 19122742      PMCID： PMC2330330          DOI： 10.1016/j.bbmt.2007.10.012

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  22 in total

Review 1.  Arrested differentiation, the self-renewing memory lymphocyte, and vaccination.

Authors:  D T Fearon; P Manders; S D Wagner
Journal:  Science       Date:  2001-07-13       Impact factor: 47.728

2.  Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells.

Authors:  Chance John Luckey; Deepta Bhattacharya; Ananda W Goldrath; Irving L Weissman; Christophe Benoist; Diane Mathis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

3.  Mouse myeloma tumor stem cells: a primary cell culture assay.

Authors:  C H Park; D E Bergsagel; E A McCulloch
Journal:  J Natl Cancer Inst       Date:  1971-02       Impact factor: 13.506

4.  The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells.

Authors:  Monica L Guzman; Randall M Rossi; Lilliana Karnischky; Xiaojie Li; Derick R Peterson; Dianna S Howard; Craig T Jordan
Journal:  Blood       Date:  2005-02-01       Impact factor: 22.113

5.  MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.

Authors:  Brian J P Huntly; Hirokazu Shigematsu; Kenji Deguchi; Benjamin H Lee; Shinichi Mizuno; Nicky Duclos; Rebecca Rowan; Sonia Amaral; David Curley; Ifor R Williams; Koichi Akashi; D Gary Gilliland
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

6.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

7.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.

Authors:  T Lapidot; C Sirard; J Vormoor; B Murdoch; T Hoang; J Caceres-Cortes; M Minden; B Paterson; M A Caligiuri; J E Dick
Journal:  Nature       Date:  1994-02-17       Impact factor: 49.962

Review 8.  Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules.

Authors:  L M Pilarski; G S Jensen
Journal:  Hematol Oncol Clin North Am       Date:  1992-04       Impact factor: 3.722

9.  Enhancement of clonogenicity of human multiple myeloma by dendritic cells.

Authors:  Anjli Kukreja; Aisha Hutchinson; Kavita Dhodapkar; Amitabha Mazumder; David Vesole; Revathi Angitapalli; Sundar Jagannath; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2006-07-31       Impact factor: 14.307

10.  The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell.

Authors:  D Billadeau; G Ahmann; P Greipp; B Van Ness
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307
View more
  2 in total

Review 1.  MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century.

Authors:  Igor Matushansky; Elizabeth Charytonowicz; Joslyn Mills; Sara Siddiqi; Todd Hricik; Carlos Cordon-Cardo
Journal:  Expert Rev Anticancer Ther       Date:  2009-08       Impact factor: 4.512

2.  A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations.

Authors:  Allison M L Nixon; Alejandro Duque; Nicholas Yelle; Megan McLaughlin; Sadegh Davoudi; Nicolas M Pedley; Jennifer Haynes; Kevin R Brown; James Pan; Traver Hart; Penney M Gilbert; Sheila K Singh; Catherine A O'Brien; Sachdev S Sidhu; Jason Moffat
Journal:  Sci Rep       Date:  2019-01-29       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.